[유한 100주년]④ 오픈이노→플랫폼 확보, 진화하는 R&D 전략

Yuhan Corp is evolving its R&D strategy from collaborative Open Innovation to internalizing next-generation platforms like Targeted Protein Degradation (TPD) and AI-driven Yu-NIVUS to lead the entire drug development lifecycle. This shift is a strategic move to secure greater commercial control and profitability, signaling a major transition for Korean pharma towards becoming original technology holders.